back-office Open An Account
partner-with-us Partner with Us
Corporate Actions
Zydus receives USFDA nod for Ivermectin and Dapsone tablets

02-Mar-26   11:29 Hrs IST
Ivermectin Tablets USP, 3 mg, are indicated for the treatment of intestinal strongyloidiasis and onchocerciasis. The drug will be manufactured at the group's formulation facility at SEZ, Ahmedabad, and marketed in the US by Viona Pharmaceuticals Inc. The product had annual sales of USD 14.8 million.

Dapsone Tablets USP, 25 mg and 100 mg are indicated for the treatment of leprosy and dermatitis herpetiformis. The tablets will be manufactured at the group's formulation facility at SEZ-II, Ahmedabad, and distributed by Viona Pharmaceuticals Inc. The product reported annual sales of USD 8.4 million in the United States (IQVIA MAT December 2025).

With this approval, the group now has 434 USFDA approvals and has filed 505 ANDAs since the commencement of filings in FY2003-04.

Zydus Life Sciences operates as an integrated pharmaceutical company with business encompassing the entire value chain in the research, development, production, marketing, and distribution of pharmaceutical products.

The company's consolidated net profit rose 7.7% to Rs 1,102.64 crore on a 32.3% increase in revenue from operations to Rs 6,780.40 crore in Q3 FY26 over Q3 FY25.

Shares of Zydus Lifesciences fell 2.09% to Rs 903.20 on the BSE.

Powered by Capital Market - Live News

Attention Investors: Stock Brokers can accept securities as margin from clients only by way of pledge in the depository system w.e.f. September 1, 2020. || Update your mobile number & email Id with your stock broker/depository participant and receive OTP directly from depository on your email id and/or mobile number to create pledge. || Pay 20% upfront margin of the transaction value to trade in cash market segment. || Investors may please refer to the Exchange's Frequently Asked Questions (FAQs) issued vide circular reference NSE/INSP/45191 dated July 31, 2020 and NSE/INSP/45534 dated August 31, 2020 and other guidelines issued from time to time in this regard. || Check your Securities /MF/ Bonds in the consolidated account statement issued by NSDL/CDSL every month.|| KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.|| No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account.